376 related articles for article (PubMed ID: 29536433)
41. Impact of recombinant human growth hormone treatment on psychological profiles in hypopituitary patients with adult-onset growth hormone deficiency.
Giusti M; Meineri I; Malagamba D; Cuttica CM; Fattacciu G; Menichini U; Rasore E; Giordano G
Eur J Clin Invest; 1998 Jan; 28(1):13-9. PubMed ID: 9502182
[TBL] [Abstract][Full Text] [Related]
42. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
Colao A; Di Somma C; Pivonello R; Loche S; Aimaretti G; Cerbone G; Faggiano A; Corneli G; Ghigo E; Lombardi G
J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
[TBL] [Abstract][Full Text] [Related]
43. The metabolic effects of short-term administration of physiological versus high doses of GH therapy in GH deficient adults.
Yuen K; Cook D; Ong K; Chatelain P; Fryklund L; Gluckman P; Ranke MB; Rosenfeld R; Dunger D
Clin Endocrinol (Oxf); 2002 Sep; 57(3):333-41. PubMed ID: 12201825
[TBL] [Abstract][Full Text] [Related]
44. Hypopituitary control and complications study (HypoCCS): a decade of an outcomes assessment observational study.
Lamberts SW
J Endocrinol Invest; 2008 Sep; 31(9 Suppl):2-5. PubMed ID: 19020377
[TBL] [Abstract][Full Text] [Related]
45. An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency.
Chihara K; Koledova E; Shimatsu A; Kato Y; Kohno H; Tanaka T; Teramoto A; Bates PC; Attanasio AF
Eur J Endocrinol; 2005 Jul; 153(1):57-65. PubMed ID: 15994746
[TBL] [Abstract][Full Text] [Related]
46. Three weekly injections (TWI) of low-dose growth hormone (GH) restore low normal circulating IGF-I concentrations and reverse cardiac abnormalities associated with adult onset GH deficiency (GHD).
Pincelli AI; Bragato R; Scacchi M; Branzi G; Osculati G; Viarengo R; Leonetti G; Cavagnini F
J Endocrinol Invest; 2003 May; 26(5):420-8. PubMed ID: 12906369
[TBL] [Abstract][Full Text] [Related]
47. Baseline characteristics and effects of ten years of growth hormone (GH) replacement therapy in adults previously treated with pituitary irradiation.
Elbornsson M; Götherström G; Bengtsson BÅ; Johannsson G; Svensson J
Growth Horm IGF Res; 2013 Dec; 23(6):249-55. PubMed ID: 24103227
[TBL] [Abstract][Full Text] [Related]
48. Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement.
Brooke AM; Kalingag LA; Miraki-Moud F; Camacho-Hübner C; Maher KT; Walker DM; Hinson JP; Monson JP
Clin Endocrinol (Oxf); 2006 Nov; 65(5):673-80. PubMed ID: 17054472
[TBL] [Abstract][Full Text] [Related]
49. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency.
Giavoli C; Profka E; Verrua E; Ronchi CL; Ferrante E; Bergamaschi S; Sala E; Malchiodi E; Lania AG; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P
J Clin Endocrinol Metab; 2012 Nov; 97(11):3983-8. PubMed ID: 22904173
[TBL] [Abstract][Full Text] [Related]
50. Effect of short-term therapy with recombinant human growth hormone (GH) on metabolic parameters and preclinical atherosclerotic markers in hypopituitary patients with growth hormone deficiency.
Benedini S; Dalle Carbonare L; Albiger N; Scanarini M; Bilora F; Petrobelli F; Giannini S; Mantero F; Scaroni C
Horm Metab Res; 2006 Jan; 38(1):16-21. PubMed ID: 16477535
[TBL] [Abstract][Full Text] [Related]
51. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
[TBL] [Abstract][Full Text] [Related]
52. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group.
Attanasio AF; Lamberts SW; Matranga AM; Birkett MA; Bates PC; Valk NK; Hilsted J; Bengtsson BA; Strasburger CJ
J Clin Endocrinol Metab; 1997 Jan; 82(1):82-8. PubMed ID: 8989238
[TBL] [Abstract][Full Text] [Related]
53. Intersubject responsiveness of high-affinity growth hormone (GH)-binding protein (GHBP) to long-term GH replacement therapy.
De Vries WR; Koppeschaar HP; Bol E; Roelen CA; Donker GH; Doerga ME; Osman-Dualeh M; Snel YE
J Endocrinol Invest; 2000; 23(7):449-56. PubMed ID: 11005269
[TBL] [Abstract][Full Text] [Related]
54. Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database.
Kelestimur F; Jonsson P; Molvalilar S; Gomez JM; Auernhammer CJ; Colak R; Koltowska-Häggström M; Goth MI
Eur J Endocrinol; 2005 Apr; 152(4):581-7. PubMed ID: 15817914
[TBL] [Abstract][Full Text] [Related]
55. Utility of P300 auditory event related potential latency in detecting cognitive dysfunction in growth hormone (GH) deficient patients with Sheehan's syndrome and effects of GH replacement therapy.
Golgeli A; Tanriverdi F; Suer C; Gokce C; Ozesmi C; Bayram F; Kelestimur F
Eur J Endocrinol; 2004 Feb; 150(2):153-9. PubMed ID: 14763913
[TBL] [Abstract][Full Text] [Related]
56. Confirmation of severe GH deficiency after final height in patients diagnosed as GH deficient during childhood.
Attanasio AF; Howell S; Bates PC; Blum WF; Frewer P; Quigley C; Shalet SM
Clin Endocrinol (Oxf); 2002 Apr; 56(4):503-7. PubMed ID: 11966743
[TBL] [Abstract][Full Text] [Related]
57. Moderate doses of hGH (0.64 mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function.
Newman CB; Frisch KA; Rosenzweig B; Roubenoff R; Rey M; Kidder T; Kong Y; Pursnani A; Sedlis SP; Schwartzbard A; Kleinberg DL
J Clin Endocrinol Metab; 2011 Jan; 96(1):122-32. PubMed ID: 20926529
[TBL] [Abstract][Full Text] [Related]
58. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
Christiansen JJ; Fisker S; Gravholt CH; Bennett P; Svenstrup B; Andersen M; Feldt-Rasmussen U; Christiansen JS; Jørgensen JO
Eur J Endocrinol; 2005 May; 152(5):719-26. PubMed ID: 15879357
[TBL] [Abstract][Full Text] [Related]
59. Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency.
Kołtowska-Häggström M; Geffner ME; Jönsson P; Monson JP; Abs R; Hána V; Höybye C; Wollmann HA
J Clin Endocrinol Metab; 2010 Jun; 95(6):2646-54. PubMed ID: 20335451
[TBL] [Abstract][Full Text] [Related]
60. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
